Mark Capone

Molecular diagnostics and personalized medicine company Myriad Genetics, Inc. (NASDAQ: MYGN) announced its fiscal third-quarter financial results Tuesday. What Happened Myriad Genetics reported better-than-expected earnings and raised its full-year 2018 guidance. The company also provided an...